論文・技術情報追加のお知らせ

1. Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database.

HPI2剤で新規有害事象シグナルと性差をFAERS解析

対象DB：FAERS

2. Pharmacovigilance evidence of drug induced urinary incontinence in the FDA adverse event reporting system.

FAERS解析で19薬剤が薬剤性尿失禁の独立危険因子と判明

対象DB：FAERS

3. Drug-induced interstitial lung disease: a real-world pharmacovigilance study based on an adverse event reporting system.

FAERS解析でDILD関連薬171種を特定し抗腫瘍薬が最多

対象DB：FAERS

4. Drug-induced movement disorder: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024.

FAERS解析で62薬剤が薬剤性運動障害リスクと関連

対象DB：FAERS

5. Inner ear signs and symptoms induced by antidepressants: a disproportionality analysis based on the FAERS database.

抗うつ薬で耳鳴やめまいなど内耳症状シグナルを検出

対象DB：FAERS

6. Reported associations between kratom and seizures: a systematic review.

クラトムと痙攣の因果関係は現時点で不十分

対象DB：FAERS

7. Psychiatric Adverse Events Associated With Dihydropyridine Calcium Channel Blockers: A Pharmacovigilance Study Based on FAERS Database.

DHP系Ca拮抗薬で自殺関連精神症状シグナルを検出

対象DB：FAERS

8. BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report.

フルマチニブでAKI症例報告もTKI全体で腎障害シグナル増加なし

対象DB：FAERS

9. Managing patients taking glucagon-like peptide-1 receptor agonists: proceed with caution.

GLP-1作動薬で胃排出遅延と誤嚥リスク上昇が指摘

対象DB：FAERS

10. Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases.

イキセキズマブで既知・新規感染関連有害事象を確認

対象DB：FAERS

11. Evaluating the risk of osteopenia-related adverse events with antiepileptic drugs: a pharmacovigilance study based on the FAERS database.

抗てんかん薬4剤で骨減少症との関連を初めて確認

対象DB：FAERS

12. Safety Evaluation of Nitroimidazole Antibiotics Based on the FAERS Database.

ニトロイミダゾール系で肝障害・不整脈など新規シグナル確認

対象DB：FAERS

13. Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database.

PI3K・mTOR阻害薬で口内炎リスク高く薬剤間差を確認

対象DB：FAERS

14. A Comprehensive Analysis of Adverse Events Associated with HER2 Inhibitors Approved for Breast Cancer Using the FDA Adverse Event Report System (FAERS).

HER2阻害薬で薬剤群別に特徴的副作用プロファイルを可視化

対象DB：FAERS

15. Steroid-Induced Thrombosis: A Comprehensive Analysis Using the FAERS Database.

性ホルモン系ステロイドで静脈血栓リスクが高いことを確認

対象DB：FAERS

16. Anaphylaxis related to fluoroquinolones: A disproportionality analysis of the FDA Adverse Event Reporting System data base.

モキシフロキサシンでアナフィラキシー報告が女性高齢者で高率

対象DB：FAERS

17. Pharmacovigilance study of adverse events of vedolizumab based on the FAERS database.

ベドリズマブで消化器障害や感染など新規シグナル検出

対象DB：FAERS

18. Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis.

メトホルミンとPPI併用で重度B12欠乏リスク上昇

対象DB：FAERS

19. Real-world FAERS safety analysis of Pralsetinib.

プラルセチニブで新規予期せぬ有害事象シグナルを検出

対象DB：FAERS

20. Safety evaluation of cinacalcet: Signal mining and analysis of adverse events based on the FAERS database.

シナカルセトで新規副作用シグナルをFAERS解析で検出

対象DB：FAERS

21. Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system.

ADCで造血毒性シグナルを特定し薬剤別特徴を解析

対象DB：FAERS

22. Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of FDA adverse event reporting system database and Japanese adverse drug event report database, and the role of pharmacists.

抗血小板薬で出血リスクと薬剤師介入効果を解析

対象DB：FAERS,JADER

23. A real-world data analysis of piroxicam in the FDA Adverse Event Reporting System (FAERS) database.

ピロキシカムで既知・新規安全性シグナルをFAERS解析

対象DB：FAERS

24. Clinical and pharmacovigilance safety evaluation of LUXTURNA((R)) (voretigene neparvovec-rzyl).

LUXTURNAで脈絡網膜萎縮など新規眼科的シグナル確認

対象DB：EudraVigilance,FAERS

25. No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis.

グリシルサイクリンで頭蓋内圧亢進シグナルは未検出

対象DB：FAERS

26. Disproportionality Analysis of Gastrointestinal Adverse Events Associated With Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report database.

T-DXdで消化器有害事象が早期発現し重篤例も確認

対象DB：JADER

27. Sex-Related Safety Signals of Sotorasib in Non-Small Cell Lung Cancer: A Real-World, Pharmacovigilance Study from the EudraVigilance Database.

ソトラシブで女性に胆汁うっ滞・肝障害シグナル確認

対象DB：EudraVigilance

28. Adverse reactions to acetaminophen and ibuprofen in pediatric patients: a narrative review.

小児で解熱鎮痛薬ADR報告増加しイブプロフェン関与高い

対象DB：EudraVigilance

29. Diverging Safety Signals: A Trend Analysis of Suspected Adverse Drug Reactions Reporting for Spinal Muscular Atrophy Therapies in the European Union.

SMA治療薬でリスジプラム等に新規安全性シグナル傾向

対象DB：EudraVigilance

30. Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

NOACとワルファリンで安全性差異をEudraVigilance解析

対象DB：EudraVigilance

31. Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database.

PPI使用で性機能障害の安全性シグナルを検出

対象DB：VigiBase

32. Nationwide Comparison of Cemented versus Uncemented Hemiarthroplasty for Femoral Neck Fractures in the Elderly: A Propensity Score-Matched Analysis Using Japan's Diagnosis Procedure Combination Database.

高齢者大腿骨頸部骨折で骨セメント使用が合併症低減

対象DB：DPC

33. Periprocedural complications after laser balloon ablation procedures for atrial fibrillation: An analysis using a nationwide claims database.

AF治療でレーザーバルーン焼灼は脳卒中リスク高い

対象DB：DPC

34. Utilization of Intensive Care Units and Outcomes Based on Admission Wards in Cardiovascular Emergencies.

心血管救急で一般病棟入院は死亡率が著しく高い

対象DB：DPC

35. Sex difference patterns in the association of low-density lipoprotein cholesterol with disease risk and all-cause mortality: A nationwide retrospective cohort study.

低LDL-C男性で全死亡・脳心疾患リスク上昇を確認

対象DB：JMDC

36. Regional Disparities in Home-Based Medical Care Utilization in Japan: Ecological Study of Nationwide Claim Data.

在宅医療利用に地域格差あり高RIJで低利用率

対象DB：NDB

37. Evaluation of the geographic distribution of patients with hepatocellular carcinoma and treatments in Japan using data from the Japanese national database.

日本のHCC地域差をNDB解析し治療標準化を確認

対象DB：NDB

38. Trends in psychiatric occupational therapy in Japan: A nationwide analysis using the National Database of Health Insurance Claims and Specific Health Checkups of Japan from 2014 to 2022.

日本で精神科作業療法入院請求が高齢・若年層で増加

対象DB：NDB

39. Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database study in Japan.

アテゾリズマブ併用で重症感染リスクは有意増加せず

対象DB：MDV

40. Improved 5-year survival with robot-assisted resection for locally advanced rectal cancer compared to laparoscopic and open surgery: A real-world cohort study.

直腸癌でロボ支援手術が長短期成績とも最優位

対象DB：MDV

41. Impact of coronavirus disease on the incidence rate of methicillin-resistant Staphylococcus aureus among hospitalized patients with lung cancer: a nationwide retrospective cohort study in Japan.

肺癌入院患者のMRSA発生率がCOVID後に減少

対象DB：MDV

42. Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan.

日本gMG患者でGC過量使用と併発症リスクを確認

対象DB：MDV

43. NT-proBNP testing for heart failure diagnosis in people with atrial fibrillation: A diagnostic accuracy study.

AF併存例でNT-proBNPはHF診断精度が低下

対象DB：CPRD

44. Comparison of the effectiveness of fast-acting insulin aspart with rapid-acting insulin analogues on glycaemic control: a retrospective cohort study using patient data from primary care practices in England.

速効型インスリン比較でFaster Aspartが有効性優位

対象DB：CPRD

45. Oral contraceptives and the risk of asthma attacks: a population-based cohort study.

プロゲステロン単剤OCP使用で喘息増悪リスク上昇

対象DB：CPRD

46. Blood pressure and adverse cardiovascular outcomes in older people with type 2 diabetes and chronic kidney disease: Findings based on the Clinical Practice Research Datalink databases in England.

高齢T2D・CKD患者で血圧未測定が最も高リスク

対象DB：CPRD

47. Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study.

DOACと抗不整脈薬併用で出血リスク増大を確認

対象DB：CPRD

48. Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.

バキスゼブリア接種後のTTSは稀で致死率約18％

対象DB：CPRD

49. Adherence to Animal Research: Reporting of In Vivo Experiments Guidelines in Stem Cell Studies in Animal Models of Parkinson's Disease: A Systematic Review.

PD動物幹細胞研究の報告遵守がARRIVE後も不十分

対象DB：KAERS

50. Incidence of Hypothyroidism and Thyroid Function Monitoring After Immune Checkpoint Inhibitor Therapy Completion for Lung Cancer: A Nationwide Analysis of a Japanese Claims Database.

ICI治療後の甲状腺機能低下症発症と監視状況を解析

対象DB：DeSC

51. Analysis of risk factors for Takotsubo cardiomyopathy in older patients using large-scale medical reimbursement data.

高齢者TTSの主因が呼吸器疾患であることを特定

対象DB：DeSC

52. Ticagrelor Paradox: Systematic Review and Network Meta-Analysis.

PLATO試験の影響を除外し抗血小板薬効果を再評価

対象DB：DeSC